Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 568

The DOI matches its Crossref record; 257 of the 257 references it cites were found in a registry or an index.

Non-small-cell lung cancer

Open access
Hendriks, Lizza E. L., Remon, Jordi, Faivre-Finn, Corinne, Garassino, Marina C., Heymach, John V., Kerr, Keith M., Tan, Daniel S. W., Veronesi, Giulia, Reck, Martin·2024·Nature Reviews Disease Primers

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41572-024-00551-9

Cites

257 of 257 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 257 references

Research works printed but not linked: 28

  1. World Health Organization. WHO Global Report on Trends in Prevalence of Tobacco Use 2000–2025, fourth edition (WHO, 2021).
  2. Akhtar-Danseh, G. G., Akhtar-Danesh, N. & Finley, C. Uptake and survival effects of minimally invasive surgery for lung cancer: a population-based study. Eur. J. Surg. Oncol. 47, 1791–1796 (2021). · doi:10.1016/j.ejso.2021.01.002
  3. WHO Classification of Tumours Editorial Board. Thoracic Tumours, WHO Classification of Tumours 5th edn, Vol. 5 (WHO, 2021).
  4. Kerr, K. M. in Molecular Pathology of Lung Cancer (eds. Cagle, P. T. et al.) 35–52 (Springer, 2012). A key overview of the molecular classification of lung cancer. · doi:10.1007/978-1-4614-3197-8_5
  5. Minna, J. D., Fong, K., Zöchbauer-Müller, S. & Gazdar, A. F. Molecular pathogenesis of lung cancer and potential translational applications. Cancer J. 8, S41–S46 (2002).
  6. Amin, M. et al. AJCC Cancer Staging Manual 8th edn (Springer, 2017).
  7. Hendriks, L. E. et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 339–357 (2023). European Society for Medical Oncology recommendations on the management of oncogene-addicted NSCLC. · DOI · Paper page
  8. Poon, C., Wilsdon, T., Sarwar, I., Roediger, A. & Yuan, M. Why is the screening rate in lung cancer still low? A seven-country analysis of the factors affecting adoption. Front. Public Health 11, 1264342 (2023). · doi:10.3389/fpubh.2023.1264342
  9. Hanash, S. M., Ostrin, E. J. & Fahrmann, J. F. Blood based biomarkers beyond genomics for lung cancer screening. Transl. Lung Cancer Res. 7, 327–335 (2018). · doi:10.21037/tlcr.2018.05.13
  10. Heiden, B. T. et al. Association between surgical quality metric adherence and overall survival among US veterans with early-stage non-small cell lung cancer. JAMA Surg. 158, 293–301 (2023). · doi:10.1001/jamasurg.2022.6826
  11. Whitson, B. A., D’Cunha, J. & Maddaus, M. A. Minimally invasive cancer surgery improves patient survival rates through less perioperative immunosuppression. Med. Hypotheses 68, 1328–1332 (2007). · doi:10.1016/j.mehy.2006.09.063
  12. Veronesi, G. et al. Robotic resection of Stage III lung cancer: an international retrospective study. Eur. J. Cardiothorac. Surg. 54, 912–919 (2018). · doi:10.1093/ejcts/ezy166
  13. Savonitto, E., Yasufuku, K. & Wallace, A. M. Robotic segmentectomy for early-stage lung cancer. Front. Surg. 10, 1090080 (2023). · doi:10.3389/fsurg.2023.1090080
  14. Veronesi, G. et al. Perioperative outcome of robotic approach versus manual videothoracoscopic major resection in patients affected by early lung cancer: results of a randomized multicentric study (ROMAN study). Front. Oncol. 11, 726408 (2021). · doi:10.3389/fonc.2021.726408
  15. Patel, Y. S. et al. RAVAL trial: protocol of an international, multi-centered, blinded, randomized controlled trial comparing robotic-assisted versus video-assisted lobectomy for early-stage lung cancer. PLoS ONE 17, e0261767 (2022). · doi:10.1371/journal.pone.0261767
  16. Houda, I. et al. OA06.03. An international EORTC survey on resectability of stage III non-small cell lung cancer. J. Thorac. Oncol. 18, S55–S56 (2023). · doi:10.1016/j.jtho.2023.09.044
  17. Dingemans, A. M. et al. OA06.05. Consensual definition of stage III NSCLC resectability: EORTC-lung cancer group initiative with other scientific societies. J. Thorac. Oncol. 18, S57–S58 (2023). · doi:10.1016/j.jtho.2023.09.046
  18. Perez, C. A. et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer 45, 2744–2753 (1980). · doi:10.1002/1097-0142(19800601)45:11<2744::aid-cncr2820451108>3.0.co;2-u
  19. Filippi, A. R. R. et al. LBA62. Durvalumab after radiotherapy (RT) in patients with unresectable stage III NSCLC ineligible for chemotherapy (CT): primary results from the DUART study. Ann. Oncol. 34, S1302 (2023). · doi:10.1016/j.annonc.2023.10.058
  20. Ko, R. et al. 1292MO. A phase II study of daily carboplatin plus irradiation followed by durvalumab for unresectable III non-small cell lung cancer patients with PS 2 or elderly (≧75 years): NEJ039A. Ann. Oncol. 34, S745–S746 (2023). · doi:10.1016/j.annonc.2023.09.770
  21. Hendriks, L. E. et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 358–376 (2023). · DOI · Paper page
  22. Genentech. Genentech reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer. gene.com https://www.gene.com/media/press-releases/14951/2022-05-10/genentech-reports-interim-results-for-ph (2022).
  23. Neal, J. et al. 60 CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy. J. Thorac. Oncol. 18, S39–S40 (2023). · doi:10.1016/s1556-0864(23)00260-5
  24. Paz-Ares, L. et al. 1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3 L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results. Ann. Oncol. 32, S953–S954 (2021). · doi:10.1016/j.annonc.2021.08.1799
  25. Ahn, M. J. et al. LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): results of the randomized phase III study TROPION-Lung01. Ann. Oncol. 34, S1305–S1306 (2023). · doi:10.1016/j.annonc.2023.10.061
  26. Sanofi announces end of program evaluating tusamitamab ravtansine after a 2 L NSCLC phase 3 trial did not meet a primary endpoint. Sanofi https://www.sanofi.com/en/media-room/press-releases/2023/2023-12-21-06-30-00-2799759 (2023).
  27. Camidge, D. R. et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: primary analysis of the LUMINOSITY trial. J. Clin. Oncol. 42, 103–103 (2024). · doi:10.1200/jco.2024.42.16_suppl.103
  28. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. Cochrane Database Syst. Rev. 5, CD007309 (2010). A Cochrane Review providing confirmation of the efficacy of chemotherapy in advanced NSCLC.

Cited by

See all 568

Metadata

Authors
Hendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M.
Venue
Nature Reviews Disease Primers
Published
2024-09-26
Volume
10
Issue
1
Pages
71-71
ISSN
2056-676X (ISSN-L)
OpenAlex
W4402886999
Cited by
568
References
257
FWCI
68.13
Type
journal article
Language
en
Open access
green
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Non-small-cell lung cancer. https://app.cochat.ai/papers/10.1038/s41572-024-00551-9
The paper
Hendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024). Non-small-cell lung cancer. Nature Reviews Disease Primers. https://doi.org/10.1038/s41572-024-00551-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.